Nektar Therapeutics vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Nektar Therapeutics (NKTR)

Q3 202614 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

September 202614 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Latest14 Aug – 7 Oct 2026

▼2▲1

Nektar's Lilly lawsuit ends with a $115M win, far below its $1B ask

Q2 loss narrower than expected, but revenue missed Nektar's second-quarter loss of $1.23 per share was far smaller than the $2.06 loss analysts expected, which supports the stock. But revenue of $10.1 million missed estimates and fell 9.8% from a year ago, so the beat came from cost control, not growth.
It is the period's first hard financial update and sets the baseline for how investors judge the company.
Cash burn stays heavy as Phase 3 trials run for years Nektar lost $40.6 million in the quarter and operating losses widened, while revenue is only non-cash royalties. Its $1.02 billion cash pile funds trials into 2028, but top-line results are not expected until mid-2028, so investors must wait years with no product sales.
It explains the core risk weighing on the stock: long, expensive trials with no near-term revenue.
Jury note in Lilly trial briefly wiped out $200M in value While the jury deliberated, a question about whether to award no damages or just $1 spooked investors, and the stock fell 11%. More than $200 million of market value vanished and never came back, showing how much the lawsuit's uncertainty was hurting the share price.
It captures the market's fear during the trial, the main event driving NKTR this period.
Lilly verdict won, but $115M is far short of the $1B sought Nektar won its contract case against Eli Lilly, with $90 million in damages plus interest totaling about $115 million, roughly 5% of its market value. That removes a legal cloud, but Nektar had sought up to $1 billion, and Lilly could still appeal.
It is the period's decisive event: a legal win that clears uncertainty but delivers far less money than hoped.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.